Thermo Fisher Scientific (BASE:TMOD) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

TMOD Panoramica delle azioni

Provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally.

Informazioni sull'azienda

TMOD analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	1/6
Prestazioni passate	2/6
Salute finanziaria	3/6
Dividendi	4/6

Premi

Si prevede che gli utili cresceranno del 15.54% all'anno

Analisi del rischio

Le azioni sono altamente illiquide

Ha un alto livello di debito

Thermo Fisher Scientific Inc. Concorrenti

Danaher

NYSE:DHR

US$198.9b

Lonza Group

SWX:LONN

CHF 38.9b

Samsung BiologicsLtd

KOSE:A207940

₩70.2t

IQVIA Holdings

NYSE:IQV

US$42.8b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Thermo Fisher Scientific
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$27.00
Massimo di 52 settimane	US$27.00
Minimo di 52 settimane	US$27.00
Beta	0.77
1Variazione di 1 mese	0%
Variazione a 3 mesi	n/a
Variazione di 1 anno	n/a
3Variazione a 3 anni	n/a
Variazione a 5 anni	n/a
Variazione dall'IPO	0%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	TMOD	AR Life Sciences	AR Mercato
7D	0%	0%	0%
1Y	n/a	0%	0%

Ritorno vs Industria: Dati insufficienti per determinare come si è comportato TMOD rispetto al settore AR Life Sciences.

Rendimento vs Mercato: Dati insufficienti per determinare la performance di TMOD rispetto al mercato AR.

Volatilità dei prezzi

Is TMOD's price volatile compared to industry and market?
TMOD volatility
TMOD Average Weekly Movement	n/a
Life Sciences Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in AR Market	0%
10% least volatile stocks in AR Market	0%

Prezzo delle azioni stabile: TMOD non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di TMOD nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1956	130,000	Marc Casper	www.thermofisher.com

Thermo Fisher Scientific Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Thermo Fisher Scientific con la sua capitalizzazione di mercato?
TMOD statistiche fondamentali
Capitalizzazione di mercato	US$200.29b
Guadagni(TTM)	US$6.02b
Ricavi(TTM)	US$43.81b

33.2x

Rapporto P/E

4.6x

Rapporto P/S

TMOD è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
TMOD Conto economico (TTM)
Ricavi	US$43.81b
Costo del fatturato	US$26.10b
Profitto lordo	US$17.71b
Altre spese	US$11.68b
Guadagni	US$6.02b

Ultimi guadagni dichiarati

Apr 01, 2023

Prossima data di guadagno

Jul 26, 2023

Utile per azione (EPS)	15.62
Margine lordo	40.42%
Margine di profitto netto	13.75%
Rapporto debito/patrimonio netto	82.8%

Come si è comportato TMOD nel lungo periodo?

Vedi performance storica e confronto

Dividendi

0.3%

Rendimento attuale del dividendo

8%

Rapporto di remunerazione

TMOD Panoramica delle azioni

Premi

Analisi del rischio

Thermo Fisher Scientific Inc. Concorrenti

NYSE:DHR

US$198.9b

SWX:LONN

CHF 38.9b

KOSE:A207940

₩70.2t

NYSE:IQV

US$42.8b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

FDA Grants Thermo Fisher Scientific Inc.'s SeCore HLA Typing Kit 510(k) Clearance for Use as Companion Diagnostic with a T-Cell Receptor Therapy for Synovial Sarcoma

Thermo Fisher Scientific Inc. Announces Extended 510k Clearance of Freelite Assays for Evaluation of MGUS

Thermo Fisher Scientific Inc. Showcases Diagnostics Innovation Across Therapeutic Areas at ADLM 2024

Thermo Fisher Scientific Inc. Raises Earnings Guidance for the Year 2024

Thermo Fisher Scientific to Help Advance Myeloid Cancer Clinical Research and Treatment Utilizing Next Generation Sequencing Technology

Thermo Fisher Scientific Inc. (NYSE:TMO) completed the acquisition of Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others.

Recent updates

FDA Grants Thermo Fisher Scientific Inc.'s SeCore HLA Typing Kit 510(k) Clearance for Use as Companion Diagnostic with a T-Cell Receptor Therapy for Synovial Sarcoma

Thermo Fisher Scientific Inc. Announces Extended 510k Clearance of Freelite Assays for Evaluation of MGUS

Thermo Fisher Scientific Inc. Showcases Diagnostics Innovation Across Therapeutic Areas at ADLM 2024

Thermo Fisher Scientific Inc. Raises Earnings Guidance for the Year 2024

Thermo Fisher Scientific to Help Advance Myeloid Cancer Clinical Research and Treatment Utilizing Next Generation Sequencing Technology

Thermo Fisher Scientific Inc. (NYSE:TMO) completed the acquisition of Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others.

Thermo Fisher Scientific Inc. to Report Q2, 2024 Results on Jul 24, 2024

Thermo Fisher Scientific Inc.(NYSE:TMO) dropped from Russell 1000 Growth-Defensive Index

Thermo Fisher Scientific Introduces the Only Fully Automated Plasmid Purification System to Help Accelerate Discovery and Development of Therapies

Thermo Fisher Scientific Introduces Thermo Scientific Heracell VIOS 250i AxD CO2 Incubators

Thermo Fisher Scientific Introduces Innovative Mass Spectrometer to Advance Clinical Research

Thermo Fisher Scientific Updates Chromosomal Microarray Analysis Solutions to Comply with IVDR Regulation

Thermo Fisher Scientific Inc. Declares Quarterly Dividend, Payable on July 15, 2024

Thermo Fisher Scientific Introduces Array-Based Solution for Extended Blood Type Research to Support Future Advancements Toward Safer Transfusions

Thermo Fisher Scientific Inc. Raises Revenue Guidance for the Full Year 2024

Thermo Fisher Scientific Inc. Introduces Animal Origin-Free Formulation to Support Scaling of Cell Therapy Manufacturing

Thermo Fisher Scientific Inc., Annual General Meeting, May 22, 2024

Thermo Fisher Scientific Introduces Its Newest Line of High Performance, Ultra-Low Temperature (ULT) Freezers

Thermo Fisher Scientific Inc. to Report Q1, 2024 Results on Apr 24, 2024

Thermo Fisher Scientific Announces A New In-Line Metrology Solution to Improve Battery Safety and Performance

Thermo Fisher Scientific Inc. Launches Corevitas Clinical Registry in Generalized Pustular Psoriasis

Thermo Fisher Scientific Inc. Increases Quarterly Cash Dividend, Payable on April 15, 2024

Thermo Fisher Scientific Inc. Launches New Ion Chromatography Instrument to Improve Reliability, Efficiency, and Functional Adaptability for Labs

Thermo Fisher Scientific Expands GMP Laboratory Service Offerings with Biosafety Testing Including Mycoplasma Testing

Thermo Fisher Scientific Inc. Announces Earnings Guidance for Full Year 2024

Thermo Fisher Scientific Appoints Srinath Venkatesh as Managing Director, India and South Asia

Thermo Fisher Scientific Receives GMP Approval from the Italian Medicines Agency for its Manufacturing Facility of RNA-Based Products in Monza, Italy

Thermo Fisher Scientific Inc. Announces Launch of Innovative Corevitas Pharmacovigilance Platform for Clinical Research Registries

Thermo Fisher Scientific Inc. Announces the Launch of the Thermo Scientific KingFisher Apex Dx and Applied Biosystems MagMAX Dx Viral/Pathogen NA Isolation Kit

Thermo Fisher Scientific Declares Quarterly Dividend, Payable on January 16, 202

Thermo Fisher Scientific Announces New Fault Localization Solution for the Analysis of Advanced Logic Semiconductors

Thermo Fisher Scientific Inc. Provides Earnings Guidance for the Year 2023

Thermo Fisher Scientific Inc. (NYSE:TMO) proposed an offer to acquire Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others for approximately $3.3 billion.

Thermo Fisher Scientific Inc. (NYSE:TMO) proposed an offer to acquire Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others for approximately $3.3 billion.

Thermo Fisher Scientific Inc. to Report Q3, 2023 Results on Oct 25, 2023

Thermo Fisher Scientific Inc. Appoints Jennifer “Jenny” Johnson to the Audit Committee

Thermo Fisher Scientific Helps Accelerate Cell Therapy Manufacturing with A Next-Generation Platform of Gibco™ CTS™ Detachable Dynabeads™

Thermo Fisher Scientific Announces the Launch of the EXENT Solution with IVDR Certification

Thermo Fisher Scientific Introduces New Chromosomal Microarray with Two-Day Turnaround Time to Increase Lab Productivity

Thermo Fisher Scientific Inc. (NYSE:TMO) acquired CorEvitas, LLC from Audax Management Company, LLC for approximately $910 million.

Thermo Fisher Scientific Announces a New Line of Thermo Scientific TM TSG Series Refrigerators

Thermo Fisher Scientific Inc. Revises earnings Guidance for 2023

Thermo Fisher Scientific Introduces New Reproductive Health Assays to Accelerate Fertility Research

Thermo Fisher Scientific Inc. Elects Jenny Johnson to Board of Directors

Thermo Fisher Scientific Inc. (NYSE:TMO) has entered into a definitive agreement to acquire CorEvitas, LLC from Audax Management Company, LLC for Approximately $910 million.

Thermo Fisher May Be Leading Bidder to Buy CorEvitas

Thermo Fisher Scientific Announces Launch of Gibco™ OncoPro™ Tumoroid Culture Medium Kit

Thermo Fisher Scientific Inc. (NYSE:TMO) completed the acquisition MarqMetrix, Inc.

Thermo Fisher Scientific Introduces Groundbreaking Mass Spectrometer to Revolutionize Biological Discovery

Thermo Fisher Scientific Inc. Declares Quarterly Cash Dividend, Payable on July 14, 2023

Montrose Environmental Group, Inc. Announces Global Collaboration with Thermo Fisher Scientific Inc. to Provide A Comprehensive Real-Time Ethylene Oxide Monitoring Solution Meets Recent Release U.S. Environmental Protection Agency Regulations

Thermo Fisher Scientific Inc., Annual General Meeting, May 24, 2023

Warburg, Advent Reportedly in Lead to Acquire Baxter's Biopharma Unit

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Thermo Fisher Scientific Inc. Riepilogo dei fondamenti

33.2x

4.6x